Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | DUT | P33316 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10953746 | 0.83 | CRBN (0.50) | CRBNDDB1ALDH1A1LMNADUT | |
| SCHEMBL24755086 | 0.82 | CRBN (0.50) | CRBNDDB1ALDH1A1LMNADUT | |
| SCHEMBL11582823 | 0.82 | CRBN (0.41) | CRBNDDB1NOTUMALDH1A1 | |
| SCHEMBL5353434 | 0.81 | CRBN (0.46) | CRBNDDB1ALDH1A1LMNADUT | |
| SCHEMBL2976955 | 0.81 | CRBN (0.48) | CRBNDDB1ALDH1A1LMNADUT | |
| SCHEMBL1526612 | 0.79 | CRBN (0.47) | CRBNDDB1ALDH1A1LMNADUT | |
| SCHEMBL5811343 | 0.78 | CRBN (0.43) | CRBNDDB1ALDH1A1LMNADUT | |
| SCHEMBL108176 | 0.78 | CRBN (0.46) | CRBNDDB1ALDH1A1LMNADUT | |
| SCHEMBL1398237 | 0.75 | CRBN (0.42) | CRBNDDB1ALDH1A1LMNADUT | |
| SCHEMBL8988100 | 0.73 | CRBN (0.45) | CRBNDDB1ALDH1A1LMNADUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | SHIVALILA CHIKDU SHAKTI (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250262235-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD (SG) | 2025-08-21 | — | — | US | disclosed |
| WO-2025072862-A9 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2025-06-26 | — | — | WO | disclosed |
| US-20250135036-A1 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2025-05-01 | — | — | US | disclosed |
| EP-4522744-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2025-03-19 | — | — | EP | disclosed |
| EP-4507700-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | Wave Life Sciences Ltd. (SG) | 2025-02-19 | — | — | EP | disclosed |
| CN-119452084-A | Oligonucleotide compositions and methods thereof | 波涛生命科学有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119317632-A | Oligonucleotide compositions and methods relating thereto | 波涛生命科学有限公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-4404942-A2 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2024-07-31 | — | — | EP | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| WO-1996011205-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1996-04-18 | — | — | WO | disclosed |
| EP-0068268-B1 | ENHANCER OF ANTI-TUMOUR EFFECT | Yamasa Shoyu Kabushiki Kaisha (JP) | 1985-05-02 | — | — | EP | disclosed |
| EP-0048022-B1 | ENHANCER OF ANTI-TUMOR EFFECT | Yamasa Shoyu Kabushiki Kaisha (JP) | 1985-01-09 | — | — | EP | disclosed |
| US-4434788-A | 3'-DEOXYGUANOSINE OR 3'-DEOXYURIDINE ADMINISTERED WITH RADIATION | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1984-03-06 | — | — | US | disclosed |
| US-4432348-A | 3'-DEOXYGUANOSINE-5'-MONOPHOSPHATE OR 3'-DEOXYADENOSINE-5'-MONOPHOSPHATE | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1984-02-21 | — | — | US | disclosed |
| EP-0045944-B1 | ENHANCER OF ANTI-TUMOR EFFECT | Yamasa Shoyu Kabushiki Kaisha (JP) | 1983-08-31 | — | — | EP | disclosed |
| EP-0079054-A1 | Enhancer of antitumor effect | Yamasa Shoyu Kabushiki Kaisha (JP) | 1983-05-18 | — | — | EP | disclosed |
| EP-0068268-A1 | Enhancer of anti-tumour effect | Yamasa Shoyu Kabushiki Kaisha (JP) | 1983-01-05 | — | — | EP | disclosed |
| EP-0048022-A2 | Enhancer of anti-tumor effect | Yamasa Shoyu Kabushiki Kaisha (JP) | 1982-03-24 | — | — | EP | disclosed |
| EP-0045944-A1 | Enhancer of anti-tumor effect | Yamasa Shoyu Kabushiki Kaisha (JP) | 1982-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | ADAR, NSUN2, RNGTT | CRBN 1532/4885DDB1 571/4885NOTUM 3265/4885 |
| US-20250262235-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | ADAR, RNGTT, NSUN2 | CRBN 3399/4885DDB1 539/4885NOTUM 1911/4885 |
| US-20250135036-A1 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | MECP2, ADAR, NSUN2 | CRBN 174/4885DDB1 621/4885NOTUM 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.